Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

作者: M. Brandão , C. Coens , M. Ignatiadis

DOI: 10.1093/ANNONC/MDZ404

关键词:

摘要:

参考文章(23)
Jürg Bernhard, Weixiu Luo, Karin Ribi, Marco Colleoni, Harold J Burstein, Carlo Tondini, Graziella Pinotti, Simon Spazzapan, Thomas Ruhstaller, Fabio Puglisi, Lorenzo Pavesi, Vani Parmar, Meredith M Regan, Olivia Pagani, Gini F Fleming, Prudence A Francis, Karen N Price, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Barbara A Walley, Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials The Lancet Oncology. ,vol. 16, pp. 848- 858 ,(2015) , 10.1016/S1470-2045(15)00049-2
D Osoba, G Rodrigues, J Myles, B Zee, J Pater, Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology. ,vol. 16, pp. 139- 144 ,(1998) , 10.1200/JCO.1998.16.1.139
Elizabeth Maunsell, Paul E. Goss, Rowan T. Chlebowski, James N. Ingle, José E. Alés-Martínez, Gloria E. Sarto, Carol J. Fabian, Pascal Pujol, Amparao Ruiz, Andrew L. Cooke, Susan Hendrix, Debra W. Thayer, Kendrith M. Rowland, Pierre Dubé, Silvana Spadafora, Sandhya Pruthi, Lavina Lickley, Susan L. Ellard, Angela M. Cheung, Jean Wactawski-Wende, Karen A. Gelmon, Dianne Johnston, Andrea Hiltz, Michael Brundage, Joseph L. Pater, Dongsheng Tu, Harriet Richardson, Quality of life in MAP.3 (Mammary Prevention 3): A randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer Journal of Clinical Oncology. ,vol. 32, pp. 1427- 1436 ,(2014) , 10.1200/JCO.2013.51.2483
David Cella, Lesley Fallowfield, Peter Barker, Jack Cuzick, Gershon Locker, Anthony Howell, , Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Research and Treatment. ,vol. 100, pp. 273- 284 ,(2006) , 10.1007/S10549-006-9260-6
Eleftherios P Mamounas, Jong-Hyeon Jeong, D Lawrence Wickerham, Roy E Smith, Patricia A Ganz, Stephanie R Land, Andrea Eisen, Louis Fehrenbacher, William B Farrar, James N Atkins, Eduardo R Pajon, Victor G Vogel, Joan F Kroener, Laura F Hutchins, André Robidoux, James L Hoehn, James N Ingle, Charles E Geyer Jr, Joseph P Costantino, Norman Wolmark, None, Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial Journal of Clinical Oncology. ,vol. 26, pp. 1965- 1971 ,(2008) , 10.1200/JCO.2007.14.0228
Lesley J. Fallowfield, Judith M. Bliss, Lucy S. Porter, Miranda H. Price, Claire F. Snowdon, Stephen E. Jones, R. Charles Coombes, Emma Hall, Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer Journal of Clinical Oncology. ,vol. 24, pp. 910- 917 ,(2006) , 10.1200/JCO.2005.03.3654
Dennis C. Sgroi, Erin Carney, Elizabeth Zarrella, Lauren Steffel, Shemeica N. Binns, Dianne M. Finkelstein, Jackie Szymonifka, Atul K. Bhan, Lois E. Shepherd, Yi Zhang, Catherine A. Schnabel, Mark G. Erlander, James N. Ingle, Peggy Porter, Hyman B. Muss, Katherine I. Pritchard, Dongsheng Tu, David L. Rimm, Paul E. Goss, Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker Journal of the National Cancer Institute. ,vol. 105, pp. 1036- 1042 ,(2013) , 10.1093/JNCI/DJT146
Jürg Bernhard, David Zahrieh, Monica Castiglione-Gertsch, Christoph Hürny, Richard D. Gelber, John F. Forbes, Elizabeth Murray, John Collins, Stefan Aebi, Beat Thürlimann, Karen N. Price, Aron Goldhirsch, Alan S. Coates, Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients—The International Breast Cancer Study Group Trial VIII Journal of Clinical Oncology. ,vol. 25, pp. 263- 270 ,(2007) , 10.1200/JCO.2005.04.5393
Patricia A. Ganz, Laura Petersen, Julienne E. Bower, Catherine M. Crespi, Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study Journal of Clinical Oncology. ,vol. 34, pp. 816- 824 ,(2016) , 10.1200/JCO.2015.64.3866
Karin Ribi, Weixiu Luo, Jürg Bernhard, Prudence A. Francis, Harold J. Burstein, Eva Ciruelos, Meritxell Bellet, Lorenzo Pavesi, Ana Lluch, Marilena Visini, Vani Parmar, Carlo Tondini, Pierre Kerbrat, Antonia Perelló, Patrick Neven, Roberto Torres, Davide Lombardi, Fabio Puglisi, Per Karlsson, Thomas Ruhstaller, Marco Colleoni, Alan S. Coates, Aron Goldhirsch, Karen N. Price, Richard D. Gelber, Meredith M. Regan, Gini F. Fleming, Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial Journal of Clinical Oncology. ,vol. 34, pp. 1601- 1610 ,(2016) , 10.1200/JCO.2015.64.8675